Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15698958 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL14709158 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL28489991 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL2362689 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL15859653 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL1834044 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL14709006 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL1509195 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL1255498 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI | |
| SCHEMBL12910763 | 1.00 | MGAM (0.33) | MGAMCA1CA2GAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218330-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| US-20110218330-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| US-20080234481-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234481-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-7381828-B2 | Triazolo pyrimidine compounds | AstraZēneca AB (SE) | 2008-06-03 | — | — | US | disclosed |
| US-7381828-B2 | Triazolo pyrimidine compounds | AstraZēneca AB (SE) | 2008-06-03 | — | — | US | disclosed |
| EP-1299390-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE IN THE PREPARATION OF A TRIAZOLO -PYRIMIDINE CARBA NUCLEOSIDE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070049755-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049755-A1 | Novel triazolo pyrimidine compounds | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049755-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | MGAM 4795/4885CA1 4866/4885CA2 4833/4885 |
| US-20080234481-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | MGAM 4795/4885CA1 4866/4885CA2 4833/4885 |
| US-20110218330-A1 | Novel triazolo pyrimidine compounds | TYMS, TYMP, DPYD | MGAM 4795/4885CA1 4866/4885CA2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.